The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.

OBJECTIVE Cost-effectiveness analyses have reported that intensive glucose control is not cost-effective in older patients with new-onset diabetes. However, these analyses have had limited data on patient preferences concerning diabetic health states. We examined how the cost- effectiveness of intensive glucose control changes with the incorporation of patient preferences. RESEARCH DESIGN AND METHODS We collected health state preferences/utilities from 519 older diabetic patients. We incorporated these utilities into an established cost-effectiveness model of intensive glucose control and compared incremental cost-effectiveness analyses ratios (ICERs) (cost divided by quality-adjusted life-year [QALY]) when using the original and patient-derived utilities for complications and treatments. RESULTS The mean utilities were approximately 0.40 for major complications, 0.76 (95% CI 0.74-0.78) for conventional glucose control, 0.77 (0.75-0.80) for intensive therapy with oral medications, and 0.64 (0.61-0.67) for intensive therapy with insulin. Incorporating our patient-derived complication utilities alone improved ICERs for intensive glucose control (e.g., patients aged 60-65 years at diagnosis, 136,000 dollars/QALY-->78,000 dollars/QALY), but intensive therapy was still not cost-effective at older ages. When patient-derived treatment utilities were also incorporated, the cost-effectiveness of intensive treatment depended on the method of glucose control. Intensive control with insulin generated fewer QALYs than conventional control. However, intensive control with oral medications was beneficial on average at all ages and had an ICER < or =100,000 dollars to age 70. CONCLUSIONS The cost-effectiveness of intensive glucose control in older patients with new-onset diabetes is highly sensitive to assumptions regarding quality of life with treatments. Cost-effectiveness analyses of diabetes care should consider the sensitivity of results to alternative utility assumptions.

[1]  M. Weinstein,et al.  The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. , 1996, JAMA.

[2]  A. Zbrozek,et al.  Model of Complications of NIDDM: I. Model construction and assumptions , 1997, Diabetes Care.

[3]  S. Kaplan,et al.  Foot infections in diabetic patients. Decision and cost-effectiveness analyses. , 1995, JAMA.

[4]  A. Zbrozek,et al.  Model of Complications of NIDDM: II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia , 1997, Diabetes Care.

[5]  Volker Foos,et al.  The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.

[6]  A S Detsky,et al.  Primer on Medical Decision Analysis: Part 3—Estimating Probabilities and Utilities , 1997, Medical decision making : an international journal of the Society for Medical Decision Making.

[7]  R. Hayward,et al.  Estimated Benefits of Glycemic Control in Microvascular Complications in Type 2 Diabetes , 1997, Annals of Internal Medicine.

[8]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[9]  R. Holman,et al.  Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. , 1999, JAMA.

[10]  C. Cowie,et al.  Sociodemographic Characteristics of Persons with Diabetes , 1996 .

[11]  Stephen W. Sorensen,et al.  The Cost-Effectiveness of Lifestyle Modification or Metformin in Preventing Type 2 Diabetes in Adults with Impaired Glucose Tolerance , 2005, Annals of Internal Medicine.

[12]  D. Singer,et al.  The epidemiology of cardiovascular disease in type 2 diabetes mellitus: how sweet it is … or is it? , 1997, The Lancet.

[13]  M. Chin,et al.  Implications of New Geriatric Diabetes Care Guidelines for the Assessment of Quality of Care in Older Patients , 2006, Medical care.

[14]  M. Engelgau,et al.  Valuing health-related quality of life in diabetes. , 2002, Diabetes care.

[15]  P. Savage,et al.  Glucose, Blood Pressure, and Lipid Control in Older People with and without Diabetes Mellitus: The Cardiovascular Health Study , 2002, Journal of the American Geriatrics Society.

[16]  M. Weinstein,et al.  Recommendations of the Panel on Cost-effectiveness in Health and Medicine. , 1996, JAMA.

[17]  Anke Richter,et al.  Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. , 2002, JAMA.

[18]  M. Weinstein,et al.  Preference-based measures in economic evaluation in health care. , 2000, Annual review of public health.

[19]  D. Singer,et al.  Non-insulin-dependent diabetes in older patients. Complications and risk factors. , 1986, The American journal of medicine.

[20]  M. Weinberger,et al.  Economic impact of diabetes mellitus in the elderly. , 1990, Clinics in geriatric medicine.

[21]  Plamen Nikolov,et al.  Economic Costs of Diabetes in the U.S. in 2002 , 2003, Diabetes care.

[22]  M. Koopmanschap,et al.  Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. , 2002, Diabetes care.

[23]  Alastair Gray,et al.  Estimating Utility Values for Health States of Type 2 Diabetic Patients Using the EQ-5D (UKPDS 62) , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  D. Ronis,et al.  BRIEF REPORT: The burden of diabetes therapy , 2005, Journal of General Internal Medicine.

[25]  Rury R. Holman,et al.  Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49) , 1999 .

[26]  T. Grist,et al.  Magnetic resonance angiography in progressive renal failure: a technology assessment. , 1995, American journal of kidney diseases : the official journal of the National Kidney Foundation.